Germany Issues Benefit Assessment For InterMune’s Esbriet, Despite Orphan Drug Status
This article was originally published in The Pink Sheet Daily
Germany’s senior health technology assessment body, the G-BA, has said that InterMune’s Esbriet is beneficial, but says it is unsure to what extent. However, such added value assessments for orphan drugs could be illegal.
You may also be interested in...
In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.
Vertex Pharmaceutical’s orphan drug for cystic fibrosis may face an additional reimbursement evaluation in Germany after IQWiG says it may breach the €50 million per year cost threshold.
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.